The future of breast cancer screening and risk-reducing strategies is being shaped by artificial intelligence (AI), according to a recent review article.

More than 100 000 women older than 70 years are diagnosed with hormone receptor-positive, early-stage breast cancer each year in the USA.1 A large proportion are at low risk of disease recurrence, ...

Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...

Oral minoxidil is a commonly prescribed treatment for hair loss. The drug is also the active ingredient in over-the-counter Rogaine. The prescription treatment is known, however, to dilate blood ...

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Women who underwent bilateral mastectomy or removal of ovaries and Fallopian tubes had lower rates of recurrence, ovarian ...

After a median follow-up of 6.1 years, patients treated with Lynparza continued to show significant improvements in survival ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

The Breast Cancer Coalition of Rochester has two grants it’s looking to award for research. Leaders at the BCCR said ...

"In BRCA carriers with prior diagnosis of breast cancer, additional challenges should be considered [before recommending a ...